ADMA Biologics Files 8-K on Financials
Ticker: ADMA · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ADMA
TL;DR
ADMA Biologics filed an 8-K on Jan 13, 2025, detailing financial results. No major surprises yet.
AI Summary
On January 13, 2025, ADMA Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing provides an update on ADMA Biologics' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36728 (identifier) — SEC File Number
- 56-2590442 (identifier) — IRS Employer Identification No.
- Ramsey, New Jersey (location) — Address of principal executive offices
- R&R ACQUISITION VI, INC (company) — Former company name
FAQ
What specific financial results are being reported by ADMA Biologics in this 8-K?
The provided excerpt indicates the 8-K concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 13, 2025.
What is ADMA Biologics, Inc.'s state of incorporation?
ADMA Biologics, Inc. is incorporated in Delaware.
What is the SEC file number for ADMA Biologics, Inc.?
The SEC file number for ADMA Biologics, Inc. is 001-36728.
Has ADMA Biologics, Inc. undergone a name change previously?
Yes, the company was formerly known as R&R ACQUISITION VI, INC, with a date of name change on July 7, 2006.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-13 07:05:29
Filing Documents
- ef20041448_8k.htm (8-K) — 28KB
- ef20041448_ex99-1.htm (EX-99.1) — 25KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-25-000870.txt ( ) — 199KB
- adma-20250113.xsd (EX-101.SCH) — 4KB
- adma-20250113_lab.xml (EX-101.LAB) — 21KB
- adma-20250113_pre.xml (EX-101.PRE) — 16KB
- ef20041448_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition On January 13, 2025, ADMA Biologics, Inc. (the "Company") issued a press release announcing the Company's preliminary unaudited full year 2024 revenue and providing a business update.*
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated January 13, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. January 13, 2025 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer